During a recent interview, Roche Chief Executive Severin
Schwan indicated that the company would likely continue its focus on
smaller-scale deal making. The company
will continue to focus on smaller acquisitions of “innovative companies” such
as its recent purchase of Intermune. “We
have to be very consistent in our approach to M&A,” Schwan noted in an interview
with the Wall Street Journal.
What the executive also addressed in that interview was the
emerging area of immunotherapy—a space which Roche reportedly plans on moving
five experimental drugs into clinical trial this year. With companies such as Bristol-Myers Squibb,
Merck and AstraZeneca all developing new therapies in this space, the competition
has become intense. Some analysts project
that the industry as a whole could be worth as much as $35 billion annually in
the future.
Schwan believes this race will be decided by those with an edge in R&D. “The winners and losers in the long term, I am absolutely sure, will be [decided by] those who do the clever combinations,” he told the newspaper.
We’ll have more on the latest in immunogenicity at the 15th
Annual Immunogenicity for Biotherapeutics event. Join us October 20-22
in Boston, MA. Download the agenda to see what’s on tap.
SAVE $100. Register
here and use code XP1938BLOG
Don’t
miss a thing. Sign up for our email
updates
Follow
us on Twitter
Join
us on LinkedIn|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment